Abstract:Depression has severely impaired the health of the people all over the world. Cognitive dysfunction due to depression has exerted serious economic burden to family and society induced by the reduction of social functioning for patients. NDRIs targeted with norepinephrine transport (hNET) and distribution than dopamine transport (hDAT) simultaneously treat depression and improve cognitive function, and they effectively avoid sexual dysfunction and other side effects. However, the drugs of NDIRs are still performing poor response to many patients. So it is urgent to discover novel NDRIs antidepressants with the ability of improving the cognitive fuction. The aim of this work was to identify novel NDRIs candicates selectively against hNET and hDAT from large compound libraries by comprehensive strategy integrating SVM, ADME/T, molecular docking, vitro binding assays, molecular dynamics simulation and binding energy calculation. Firstly, 6,522 compounds without inhibiting serotonin transporter (hSERT) were hitted by SVM models of hNET, hDAT and non-target hSERT with similarities analysis from compound libraries. ADME/T and molecular docking were then used to filter compounds which could potently bind in hNET and hDAT with good ADME/T, and 4 compounds were successfully identified. According to their docking scors and ADME/T information, 3719810 was advanced for profiling in vitro assays as novel NDRIs lead compound attributing to its best druggability and balance activities. Encouragingly, 3719810 performed comparative activities on two targets with Ki value 7.32 μM for hNET and 5.23μM for hDAT. In order to abtain candicates with more activities and balance activities of 2 targets, 5 analogs were optimized and 2 novel scaffold compounds were successively designed. By assessment of molecular docking, molecular dynamics simulation and binding energy calculation, 5 compounds were validated as NDRIs candicates with high activties, and 4 out of them performed acceptable balance actives acting on hNET and hDAT, which could supply promising novel NDRIs to exploit drugs for depression with cognitive dysfunction or other related neruodegenrative disorders, and also shed sight on screening inhibitors for dual-target with homological non-target on highly efficient and cost-effective.

Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study

Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study.

Stereochemical optimization of N,2-substituted cycloalkylamines as norepinephrine reuptake inhibitors

Computational Characterization of the Selective Inhibition of Human Norepinephrine and Serotonin Transporters by an Escitalopram Scaffold

Differentiating Physicochemical Properties Between NDRIs and Snris Clinically Important for the Treatment of ADHD.

What Contributes to SNRIs' Dual-targeting Mechanism? The Key Role of TM6 Domain in hSERT and hNET Revealed by Molecular Dynamics Simulation.

Understanding The Polypharmacological Profiles Of Triple Reuptake Inhibitors By Molecular Simulation

Molecular basis of human noradrenaline transporter reuptake and inhibition

Substrate binding and inhibition mechanism of norepinephrine transporter

Exploring Unbinding Mechanism of Drugs from SERT Via Molecular Dynamics Simulation and Its Implication in Antidepressants

Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors.

Uncovering the Elusive Structures and Mechanisms of Prevalent Antidepressants

Structural Models of Human Norepinephrine Transporter Ensemble Reveal the Allosteric Sites and Ligand-Binding Mechanism

Comparison of computational model and X-ray crystal structure of human serotonin transporter: potential application for the pharmacology of human monoamine transporters

Interaction of antidepressants with the serotonin and norepinephrine transporters: mutational studies of the S1 substrate binding pocket

A Multiple-step Screening Protocol to Identify Norepinephrine and Dopamine Reuptake Inhibitors for Depression

QSAR modeling, molecular docking and ADMET/pharmacokinetic studies: a chemometrics approach to search for novel inhibitors of norepinephrine transporter as potent antipsychotic drugs

Molecular Mechanism for the Allosteric Inhibition of the Human Serotonin Transporter by Antidepressant Escitalopram

Revealing Vilazodone's Binding Mechanism Underlying Its Partial Agonism to the 5-HT1A Receptor in the Treatment of Major Depressive Disorder

Synthesis and preliminary evaluation of benzylaminoimidazoline derivatives as novel norepinephrine transporter ligands

Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters